ReShape Lifesciences Inc.
RSLS
$0.365
-$0.015-3.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -11.39% | 0.88% | 27.27% | -29.15% | 51.95% |
| Total Depreciation and Amortization | 0.00% | -16.67% | 0.00% | -14.29% | -86.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 51.15% | 1,107.69% | 92.33% | -6,680.00% | -100.54% |
| Change in Net Operating Assets | -32.90% | 288.76% | -43.17% | 159.66% | -249.08% |
| Cash from Operations | -120.90% | 77.08% | 34.51% | 15.67% | 11.62% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 200.00% |
| Cash from Financing | -- | -100.00% | -- | -- | 1,715.68% |
| Foreign Exchange rate Adjustments | -1,700.00% | -85.71% | 187.50% | -233.33% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 83.87% | 76.62% | 36.25% | -169.10% | 196.54% |